Adenoma of the middle ear  by Hong-jun, Xiao et al.
Journal of Otology 2007 Vol. 2 No. 2
Adenoma of the middle ear
XIAO Hong-jun1, WEI Yong-hao1, NIE Xiu2
1 Department of Otolaryngology, 2 Department of Pathology, Union Hospital, Tongji Medical
College, Huazhong University of Science and Technology. Wuhan 430022, Hubei.
Adenoma of the middle ear is a primary tumor of
the middle ear that can have exocrine (mucinous) and/
or neuroendocrine differentiation. It is an uncommon
tumor in the practice of otolaryngology. Based on the
first description by Hyams and Michael in 1976,
adenoma of the middle ear is defined as a benign
adenomatous tumor arising from the middle ear
mucosa. To date, there have been over 100 cases
reported in English literature, but none by Chinese
authors. However, two cases of "carcinoid tumor of the
middle ear" have been reported in Chinese literature［1,
2］. These middle ear tumors with predominantly
neuroendocrine differentiation are now known to be
adenomas. For its rarity, debates still exist regarding its
histogenesis, grading and nomenclature. In this paper,
we review the literature on middle ear adenoma with
an eye toward improving its diagnosis and
management.
Anatomical background
The middle ear, bounded by the tympanic mem-
brane and inner ear, contains the malleus, incus and sta-
pes, the opening of the eustachian tube, the attic (epi-
tympanic recess) and the mastoid cavity.
There is a progressive transition in the
histological appearance of the middle ear mucosa from
the Eustachian tube to the mastoid. Pseudostratified
and cylindrical epithelium covers the anterior third of
the tympanic cavity, whereas epithelium in the middle
portion of the cavity can have up to three layers of
cells. The posterior third of the tympanic cavity, the
antrum of the mastoid, and the ossicles are covered by
single layer of cells. The majority of middle ear
epithelial cells are not ciliated, except for those of the
anterior third around the opening of the Eustachian
tube. Tubuloalveolar seromucosal glands are found in
the lamina propria of the pharyngeal part of the
Eustachian tube, whereas the tympanic cavity, the
antrum, and the mastoid do not have such
components［3］. Two types of secretory cells can be
identified in normal mucosa of the middle ear: goblet
and intermediate cells.
Embryologically, the middle ear epithelium is an
endodermal (foregut) derivative, while mesenchymal
elements of the middle ear (including the ossicles) are
derived from mesodermal elements of the branchial
arch［4］.
Histogenesis and nomenclature
Early authors described adenoma of the middle
ear as a benign adenomatous tumor arising from the
mucosal epithelium. Later, others found that some glan-
dular tumors of the middle ear, otherwise apparently
identical to an adenoma, showed neuroendocrine fea-
tures(i.e., positive Grimelius staining, abundance of
membrane-bound granules on electron microscopy and
expression of neuroendocrine immunohistochemical
markers). These are termed "carcinoid tumor of the
middle ear".
Typical carcinoid tumor, by definition, is a
low-grade malignant neoplasm. They are more
commonly diagnosed in the lung, pancreas and
gastrointestinal tract. It is well-known that carcinoid
tumor originate from neuroendocrine cells that are
dispersed throughout these tissues. Neuroendocrine
cells are derived from pluripotential endodermal stem
cells and can secrete hormones. However,
neuroendocrine cells have not been identified either in
normal or inflamed middle ear mucosa, although an
undifferentiated, pluripotential endodermal stem cell
may still be present within the surface mucosa of the
middle ear.
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However, some authors have found
immunohistochemical and ultrastructural evidence that
both adenoma and carcinoid tumor of the middle ear
show features of exocrine(mucinous) and
neuroendocrine differentiation, although the proportion
of the two types of differentiation is different [5~8].
Therefore, debates remain regarding whether carcinoid
tumors of the middle ear represent an entity distinct
from middle ear adenoma. The confusion results from
histopathologic similarities between tumors classified
under both terms, inaccurate and inconsistent
terminology for middle ear tumors, uncertainty
regarding histogenesis, and similarities in biological
behavior.
Multiple recent studies have demonstrated that
these terms describe the same tumor, which can have
mixed patterns of differentiation ［9~11］. Tumors with
either exocrine(mucinous) or neuroendocrine
differentiation most likely represent opposite ends of
the spectrum of differentiation. Based on a
histopathologic and immunohistochemical study of 48
cases, Torske et al［11］ suggested using "neuroendocrine
adenoma of the middle ear" as a more descriptive term,
for it not only reflects its dual nature but also its benign
clinical behavior. Moreover, they propose an
undifferentiated, pluripotential endodermal stem cell to
be the origin of the tumor.
In the World Heath Organization (WHO)
Classification of Tumors (2005), adenoma of the
middle ear is defined as a benign glandular neoplasm
showing variable differentiation along neuroendocrine
and mucin-secreting pathways. Middle ear
adenomatous tumor, neuroendocrine adenoma of the
middle ear and carcinoid tumor of the middle ear are
considered the synonyms of adenoma of the middle ear
in the WHO classification ［12］. This proposal is
gradually accepted by Otolaryngologists and
Pathologists.
Pathologic findings
Intraoperative examination of middle ear
adenomas often shows solid neoplasms, apparently
encapsulated and not particularly vascular, usually
white, gray, or reddish brown in color. They can be
easily peeled off the bony walls of the middle ear but
may entrap and destroy the ossicles. Torske et al ［11］
reported tumor sizes ranging from 0.2 to 3.0 cm, with
an average of 0.8 cm. Ramsey et al ［13］ reported
ossicular involvement in 72% (33/46) of their cases,
with 20% mastoid involvement and 9% eustachian
tube involvement rates.
On routine light microscopy, the histological
architectural patterns of middle ear adenomas can be
solid, glandular, or trabecular. Over 81% of cases
present with more than one pattern［11］. Tumor cells are
usually uniform and can be cuboidal or cylindrical.
They have a moderate amount of acidophilic
cytoplasm and may assume a plasmacytoid appearance
［14］. Nuclei are round to oval with a "salt and pepper"
chromatin pattern and inconspicuous nucleoli.
Moderate to marked nuclear pleomorphism can occur,
but neither mitotic activity nor necrosis are features of
middle ear adenoma ［15］. The tumors can produce
mucin, which is positive on periodic acid-Schiff, alcian
blue, and mucicarmine stains. Papillary features are not
present in a middle ear adenoma. However, sheet-like
and disorganized areas can be identified in some cases
of middle ear adenoma which may be artifactual and
related to surgical tugging on the specimen at resection.
In a study involving 48 cases, middle ear
adenomas were positive for cytokeratin(CK) cocktails
(90% ), CAM 5.2 (81% ), and CK7 (90% ). Staining
with CK7 highlighted the luminal surface of glandular
cells. Only focally and weakly positive results were
observed with CK20(6% ). Neuroendocrine markers
such as chromogranin(88% ), neuron-specific
enolase(50% ), synaptophysin(31% ), and
serotonin(25%) were positive, but not all markers were
positive in a single case. Neuroendocrine markers were
positive within the basal cell layer of the glandular
elements. They were more diffusely positive in other
architectural patterns. Reactivity, however, was not
uniform and varied both between cases and in levels of
intensity. Human pancreatic polypeptide was focally
positive in most cases(94% ), and S-100 protein was
positive in some stromal cells (18% ) or tumor cells
(15%)［11］.
We recently treated a case of middle ear adenoma
in a 27-year-old man presenting with aural fullness, tin-
nitus of one year and hearing loss of one month. The tu-
mor was gray-white, soft and about 0.5×0.5 cm in size.
Histological sections of the tumor showed regular, co-
lumnar or cuboidal eosinophilic cells arranged in solid,
trabecular and glandular areas(Fig 1 and 2). Mild nu-
clear pleomorphism was present, and mitotic figures
were absent. The tumor was immunohistochemically
positive for CK8/18 and synaptophysin and negative
for S-100 protein and P63 (Fig 3 and 4).
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Ultrastructural examination of five cases showed
basally situated cells and solid tumour cells(cell B)
containing neuroendocrine granules which were
positive for neuroendocrine makers. This was in
contrast to apically situated dark cells(cell A) which
contained mucous granules, reacted with antikeratin
and antiepithelial membrane antigen antibodies but
stained negative for neuroendocrine makers［3, 12］. Both
cells A and B were small, rounded, regular and
hyperchromatic, without mitosis or atypical core.
The value of frozen section is controversial, as
some middle ear adenomas have been mistaken for
adenocarcinomas on frozen section. In a series of 32
frozen sections of middle ear adenomas, the final
diagnosis of middle ear adenoma was not made in any
case by frozen section. Some of the diagnoses were
paraganglioma(21 cases), chronic otitis media (6
cases), and cholesteatoma(5 cases)［16］. However, Jones
at el reported a case diagnosed on frozen section
biopsies, which helped avoiding unnecessary
procedures［17］.
No molecular genetic studies have been
conducted on middle ear adenomas. The tumor is not
reported to occur in families［12］.
Clinical features
Adenoma of the middle ear is an uncommon
neoplasm and constitutes about 4% of aural tumors［11］.
Patient age ranges from 14 to 80 years, with no sex
predominance. The mean age is about 45 years. All
patients present with unilateral disease, with no side
predominance. The most common symptom is hearing
loss, followed by a mass and aural pain ［4, 11, 13, 15］.
Retrospectively reviewing 48 cases of middle ear
adenoma, Torske et al found that 69% of the patients
presented with hearing loss, followed by a mass (25%),
aural pain (24%), discharge (14%), tinnitus (12%) and
facial nerve weakness (8% ) ［11］. These were similar
with Ramsey's report［13］. The duration of symptoms
ranged from 1 to 228 months, with an average of 21
months. Some patients presented with no symptoms
and the tumors were detected at the time of routine
physical examination.
Otoscopy often shows an intact tympanic membrane
in the first stage with a dark brown reddish colored
structure behind it. Sometimes this mass distorts the
tympanic membrane, bending in the direction of the
external auditory canal. Tumor may later expand and
penetrate the tympanic membrane. For some patients,
an external auditory canal mass can be the only finding
at the time of diagnosis. A middle ear mass can
develop later.
Audiometry examination identifies a conductive
hearing loss in the majority of patients with middle ear
Fig1. Solid area of the tumor (hematoxylin-eo-
sin, original magnification × 400). Fig 2. Tra-
becular area of the tumor (hematoxylin-eosin,
original magnification ×400). Fig3. Neuroen-
docrine differentiation demonstrated by synap-
tophysin positive immunohistochemical stain-
ing(immunoperoxidase method, original mag-
nificayion ×400). Fig 4. Epithelial differenti-
ation demonstrated by CK8/18 positive immu-
nohistochemical staining (immunoperoxidase
method, original magnification × 400). Fig 5.
CT of the temporal bone showing a soft tissue
density mass within the right tympanic cavity (the ossicles are embedded).
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adenoma, and sensorineural hearing loss(SNHL) in
some patients. The conductive loss of approximately
30 dB prevails in the conversational frequencies.
Computed tomography(CT) of the temporal bone
is a key procedure. It highlights a nonspecific
soft-tissue density, well limited mass in the tympanic
cavity without bone invasion and poses mainly the
differential diagnosis from a glomic tumor. Sometimes
ossicular entrapment and destruction can be observed.
On magnetic resonance imaging(MRI), these tumors
often have brain-like signal intensity on both T1- and
T2-weighted images, with no significant enhancement
after intravenous gadolinium［18］.
For our patient, pure tone audiometry showed a
mix hearing loss of 48 dB HL in the right ear with a 15
dB air-bone gap. Hearing was normal in his left ear.
Temporal bone CT revealed a soft tissue density mass
within the right tympanic cavity entrapping the ossicles
(Fig 5).
Diagnosis and differential diagnosis
For its nonspecific findings in the clinic and on
imaging studies, the diagnosis of adenoma of the
middle ear depends mainly on post-operative
pathologic examination. Indolent course, CT
examination, typical features of histopathology and
findings of immunohistochemical examinaton compose
of the main factors in the diagnosis of adenoma of the
middle ear.
The differential diagnosis of benign tumors of the
middle ear includes middle ear adenoma,
paraganglioma and schwannoma ［19］. A paraganglioma
is composed of uniform epithelioid cells, which are
grouped in ball-like cell clusters or zellballen. These
clusters are surrounded by spindle-shaped
sustentacular cells. The epitheloid cells are
immunohistochemically positive for neuroendocrine
markers, such as synaptophysin and chromogranin A.
The epitheloid cells are immunohistochemically
negative for cytokeratin markers. The sustentacular
cells are immunohistochemically positive for S100
protein. A schwannoma is a benign nerve sheath tumor
composed of Schwann cells. These form hypercellular
areas (Antoni A areas) and hypocellular areas (Antoni
B areas). They may contain Verocay bodies, which are
composed of 2 parallel columns of palisading cells.
Schwannomas are diffusely immunohistochemically
positive for S100 protein.
The differential diagnosis of middle ear lesions
also includes other benign lesions such as
cholesteatoma and chronic otitis media. A
cholesteatoma is composed of anucleate keratin-filled
squamous cells with foreign body giant cells and
hemosiderin. Cholesteatoma can be diagnosis
according to its distinct macroscopy and
histopathology. Chronic otitis media can have
glandular metaplasia as well as chronic inflammation
and granulation tissue.
Malignant tumors of the middle ear, such as
adenocarcinoma, must be distinguished from middle
ear adenoma［20］. Adenocarcinomas of the middle ear
are often metastasis from other sites. Based on its
benign biologic behavior, mature tumor cell
differentiation and CT findings, middle ear adenoma
can be distinguished from adenocarcinoma.
Management
Surgical excision constitutes the only curative
treatment of the lesion. No additional therapy is
recommended in the literature. Surgical excision also
allows histological analysis of the lesion and
exploration of the entire tympanic cavity and the
mastoid. Excision must be complete and constitutes the
only possibility of no recurrence.
The pre-operative evaluation mainly consists of
otoscopy, CT of the temporal bone and audiometry
examination. The surgical procedure mainly consists of
radical mastoidectomy or tympanotomy. In a
retrospective review of 46 cases, 48% of the patients
underwent radical mastoidectomy whereas 34%
patients underwent tympanotomy. A 29% of recurrence
rate was related to tympanotomy versus 10% to radical
mastoidectomy［13］.
If the tumor entraps the ossicles, the ossicles are
often recommended to be partly removed to ensure
complete excision of the tumor. As the ear with middle
ear adenoma often has normal Eustachian tube
function and middle ear mucosa, ossiculoplasty should
have a successful outcome［3］.
Prognosis
Middle ear adenomas have a good prognosis after
surgical excision and most tumors do not recur.
Recurrence has occurred after incomplete surgical
resection. No patient deaths were reported in a series of
48 cases. Eight of these cases were recurrent, but they
were successfully treated with surgical resection［11］.
Some authors have reported that facial nerve
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involvement is a poor prognostic indicator. However,
others have indicated that facial nerve involvement is
most likely related to nerve compression and not
invasion. Facial nerve symptoms may resolve after
resection ［21］. Unlike carcinoid tumors of the lung,
which have a metastatic rate of less than 23%, only 4
cases of middle ear adenoma metastasis have been
reported［13］. One of these cases was cervical lymph
node metastasis, and the other three cases were
intraparotid lymph nodes. No case with distal
metastasis has been reported.
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